GLP1R and Obesity: Finally, prospective trials specifically designed to evaluate GLP-1 RAs in high-risk subpopulations—such as older adults with obesity or heart failure—would help validate these findings, inform optimal dosing strategies, and support the development of personalized therapeutic approaches.